Used in the development of immunotherapies targeting bone-related diseases such as osteoporosis and cancers. Specifically engineered to modulate immune responses by binding to Siglec-15, a protein involved in suppressing T-cell activity in the tumor microenvironment and regulating osteoclast function. This antibody helps restore anti-tumor immunity, making it a candidate for cancer immunotherapy, particularly in solid tumors with high Siglec-15 expression, including those resistant to PD-1/PD-L1 inhibitors. Siglec-15 is often abundant in M2-like tumor-associated macrophages and certain tumor cells. Also investigated for its role in treating bone disorders. Serves as a reference in preclinical studies and assay development for evaluating anti-Siglec-15 therapeutic candidates.